Joint (JYNT)


Market Price (9/21/2026): $8.44 | Market Cap: $120.2 MilSector: Health Care | Industry: Health Care Facilities

Joint (JYNT)


Market Price (9/21/2026): $8.44
Market Cap: $120.2 Mil
Sector: Health Care
Industry: Health Care Facilities

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -17%

Low stock price volatility
Vol 12M is 37%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Health & Wellness Trends. Themes include Geriatric Care, Preventative Healthcare, Show more.

Weak multi-year price returns
2Y Excs Rtn is -66%, 3Y Excs Rtn is -81%

Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 73x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 22x, P/EPrice/Earnings or Price/(Net Income) is 32x

Key risks
JYNT key risks include [1] a history of financial restatements and material weaknesses in internal controls and [2] decelerating growth fueled by marketing inefficiency and high SG&A expenses.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -17%
1 Low stock price volatility
Vol 12M is 37%
2 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Health & Wellness Trends. Themes include Geriatric Care, Preventative Healthcare, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -66%, 3Y Excs Rtn is -81%
4 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 73x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 22x, P/EPrice/Earnings or Price/(Net Income) is 32x
5 Key risks
JYNT key risks include [1] a history of financial restatements and material weaknesses in internal controls and [2] decelerating growth fueled by marketing inefficiency and high SG&A expenses.

JYNT in ETFs

Weight = JYNT's share of each fund

VTI0.00%
DFAS0.00%
DFAC0.00%
AVUV0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 9/14/2026

Joint (JYNT) stock has lost about 5% since 5/31/2026 because of the following key factors:

1. Decline in System-Wide and Comparable Clinic Sales in Fiscal Q2 2026.

The Joint Corp. reported a 3.7% decrease in system-wide sales for fiscal Q2 2026, which ended June 30, 2026, compared to the second quarter of the previous year. Additionally, comparable clinic sales experienced a decline of 2.8% during fiscal Q2 2026.

2. Reduction in Full-Year Guidance for New Clinic Openings.

Following its fiscal Q2 2026 earnings report, The Joint Corp. lowered its guidance for new franchise clinic openings for fiscal year 2026. The company revised its projection to 22-26 new clinics, down from the previous range of 30-35. Management also indicated that the year-end net clinic count is expected to be lower than fiscal year 2025 levels.

Show more
Updated on 9/14/2026

Joint (JYNT) stock has lost about 5% since 5/31/2026 because of the following key factors:

1. Decline in System-Wide and Comparable Clinic Sales in Fiscal Q2 2026.

The Joint Corp. reported a 3.7% decrease in system-wide sales for fiscal Q2 2026, which ended June 30, 2026, compared to the second quarter of the previous year. Additionally, comparable clinic sales experienced a decline of 2.8% during fiscal Q2 2026.

2. Reduction in Full-Year Guidance for New Clinic Openings.

Following its fiscal Q2 2026 earnings report, The Joint Corp. lowered its guidance for new franchise clinic openings for fiscal year 2026. The company revised its projection to 22-26 new clinics, down from the previous range of 30-35. Management also indicated that the year-end net clinic count is expected to be lower than fiscal year 2025 levels.

3. Analyst Downgrades Following Q2 2026 Results.

Several analyst firms revised their ratings for JYNT stock in the period following the fiscal Q2 2026 earnings announcement. Zacks Research downgraded Joint from a "strong-buy" to a "hold" rating on July 7, 2026, and Wall Street Zen subsequently cut its rating from a "strong-buy" to a "buy" on August 16, 2026.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -5.2% change in JYNT stock from 5/31/2026 to 9/20/2026 was primarily driven by a -18.8% change in the company's P/E Multiple.
(LTM values as of)53120269202026Change
Stock Price ($)8.908.44-5.2%
Change Contribution By: 
Total Revenues ($ Mil)57593.4%
Net Income Margin (%)5.7%6.5%13.5%
P/E Multiple39.031.7-18.8%
Shares Outstanding (Mil)1414-0.4%
Cumulative Contribution-5.2%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2026 to 9/20/2026
ReturnCorrelation
JYNT-5.2% 
Market (SPY)0.9%14.4%
Sector (XLV)12.7%-0.2%

Fundamental Drivers

The -4.1% change in JYNT stock from 2/28/2026 to 9/20/2026 was primarily driven by a -54.7% change in the company's P/E Multiple.
(LTM values as of)22820269202026Change
Stock Price ($)8.808.44-4.1%
Change Contribution By: 
Total Revenues ($ Mil)54597.5%
Net Income Margin (%)3.6%6.5%82.6%
P/E Multiple69.831.7-54.7%
Shares Outstanding (Mil)15147.7%
Cumulative Contribution-4.1%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2026 to 9/20/2026
ReturnCorrelation
JYNT-4.1% 
Market (SPY)11.6%19.3%
Sector (XLV)5.5%8.0%

Fundamental Drivers

The -21.4% change in JYNT stock from 8/31/2025 to 9/20/2026 was primarily driven by a -33.0% change in the company's P/S Multiple.
(LTM values as of)83120259202026Change
Stock Price ($)10.748.44-21.4%
Change Contribution By: 
Total Revenues ($ Mil)54599.0%
P/S Multiple3.12.1-33.0%
Shares Outstanding (Mil)15147.6%
Cumulative Contribution-21.4%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2025 to 9/20/2026
ReturnCorrelation
JYNT-21.4% 
Market (SPY)19.4%26.3%
Sector (XLV)24.1%14.3%

Fundamental Drivers

The -9.1% change in JYNT stock from 8/31/2023 to 9/20/2026 was primarily driven by a -45.4% change in the company's Total Revenues ($ Mil).
(LTM values as of)83120239202026Change
Stock Price ($)9.298.44-9.1%
Change Contribution By: 
Total Revenues ($ Mil)10759-45.4%
Net Income Margin (%)2.7%6.5%136.1%
P/E Multiple45.931.7-31.0%
Shares Outstanding (Mil)15142.3%
Cumulative Contribution-9.1%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2023 to 9/20/2026
ReturnCorrelation
JYNT-9.1% 
Market (SPY)75.6%29.4%
Sector (XLV)32.3%22.1%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
JYNT Return150%-79%-31%11%-18%-3%-68%
Peers Return16%-35%-10%16%-12%26%-12%
S&P 500 Return27%-19%24%23%16%12%103%

Monthly Win Rates [3]
JYNT Win Rate58%25%33%58%58%56% 
Peers Win Rate48%38%42%54%44%33% 
S&P 500 Win Rate75%42%67%75%67%44% 

Max Drawdowns [4]
JYNT Max Drawdown-43%-80%-62%-44%-40%-25% 
Peers Max Drawdown-42%-54%-54%-31%-36%-39% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: USPH, PLNT, LTH, XWEL. See JYNT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/18/2026 (YTD)

How Low Can It Go

EventJYNTS&P 500
2025 US Tariff Shock
  % Loss-15.3%-18.8%
  % Gain to Breakeven18.0%23.1%
  Time to Breakeven45 days79 days
2024 Yen Carry Trade Unwind
  % Loss-10.7%-7.8%
  % Gain to Breakeven12.0%8.5%
  Time to Breakeven223 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-44.4%-9.5%
  % Gain to Breakeven80.0%10.5%
  Time to Breakeven176 days24 days
2023 SVB Regional Banking Crisis
  % Loss-14.9%-6.7%
  % Gain to Breakeven17.5%7.1%
  Time to Breakeven315 days31 days
2020 COVID-19 Crash
  % Loss-51.4%-33.7%
  % Gain to Breakeven105.8%50.9%
  Time to Breakeven82 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-22.3%-19.2%
  % Gain to Breakeven28.7%23.8%
  Time to Breakeven56 days105 days

Compare to USPH, PLNT, LTH, XWEL

In The Past

Joint's stock fell -15.3% during the 2025 US Tariff Shock. Such a loss loss requires a 18.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventJYNTS&P 500
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-44.4%-9.5%
  % Gain to Breakeven80.0%10.5%
  Time to Breakeven176 days24 days
2020 COVID-19 Crash
  % Loss-51.4%-33.7%
  % Gain to Breakeven105.8%50.9%
  Time to Breakeven82 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-22.3%-19.2%
  % Gain to Breakeven28.7%23.8%
  Time to Breakeven56 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-64.8%-12.2%
  % Gain to Breakeven183.8%13.9%
  Time to Breakeven820 days62 days
2014-2016 Oil Price Collapse
  % Loss-43.9%-6.8%
  % Gain to Breakeven78.3%7.3%
  Time to Breakeven776 days15 days

Compare to USPH, PLNT, LTH, XWEL

In The Past

Joint's stock fell -15.3% during the 2025 US Tariff Shock. Such a loss loss requires a 18.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Joint (JYNT)

```html

The Joint Corp. (JYNT) is a publicly traded healthcare company focused on delivering chiropractic care services. The company's core business involves the development, ownership, operation, support, and management of a network of chiropractic clinics across the United States. Its primary offering is accessible chiropractic adjustments and related non-surgical spinal care, designed to provide convenient and affordable solutions for individuals seeking relief from musculoskeletal issues, improved mobility, and overall wellness.

JYNT expands its market presence through a dual operating model, encompassing both directly owned and managed "Corporate Clinics" and "Franchise Operations." This hybrid strategy leverages direct ownership, management arrangements, franchising to independent operators, and partnerships with regional developers to grow its footprint. As of early 2022, The Joint Corp. had established a significant national presence with approximately 700 locations, primarily serving individuals seeking routine or acute chiropractic care.

```

AI Analysis | Feedback

Here are a few analogies for The Joint Corp. (JYNT):

  • The Great Clips of chiropractic clinics.
  • A Starbucks for chiropractic adjustments.

AI Analysis | Feedback

```html
  • Chiropractic Care: Direct provision of chiropractic adjustments and related services to patients through its network of clinics.
  • Franchise Operations: Offering opportunities to individuals and entities to own and operate chiropractic clinics under The Joint Corp. brand and system.
  • Clinic Management and Support: Providing operational, developmental, and support services for both corporate-owned and franchised chiropractic clinics.
```

AI Analysis | Feedback

The Joint Corp. (JYNT) operates chiropractic clinics, which provide direct healthcare services to individuals. Therefore, the company primarily sells its services to individuals.

The major categories of individual customers served by The Joint Corp. include:

  1. Individuals seeking pain relief: This category encompasses patients experiencing acute or chronic musculoskeletal pain, such as back pain, neck pain, headaches, and sciatica, who seek chiropractic adjustments for symptom alleviation and recovery.
  2. Individuals seeking wellness and preventative care: Customers in this group may not be experiencing acute pain but choose chiropractic care for ongoing spinal health maintenance, improved posture, stress reduction, and overall well-being. They often receive regular, routine adjustments.
  3. Athletes and active individuals: This segment includes people who use chiropractic services for performance enhancement, injury prevention, faster recovery from physical activity, and to maintain optimal bodily function to support their active lifestyles.

AI Analysis | Feedback

null

AI Analysis | Feedback

Sanjiv Razdan, Chief Executive Officer

Sanjiv Razdan joined The Joint in 2024, bringing over 35 years of experience in franchising and hospitality. He has a strong background in growing and leading successful multi-unit companies and franchise businesses. Before joining The Joint, he was President of Americas and India for The Coffee Bean & Tea Leaf, a global specialty coffee and tea house company. Razdan also held senior operations leadership roles at prominent franchisors such as Yum! Brands (Pizza Hut and KFC), Dine Brands (Applebee's), and Sweetgreen. He earned a Bachelor of Science degree in Physics and Computer Science from St. Xavier's College in Mumbai, India, completed a post-graduate program in Hotel Administration with ITC Hotels, and holds a certificate from Cornell University in QSR Management.

Scott J. Bowman, Chief Financial Officer

Scott J. Bowman became Chief Financial Officer of The Joint Corp. on June 10, 2025. He is a seasoned executive and a three-time public company CFO, with over 30 years of experience across the retail, restaurant, consumer goods, and manufacturing industries. Prior to The Joint, Bowman served as CFO at Leslie's Inc., a publicly held pool supply retailer (2023-2025), True Food Kitchen, a privately held restaurant company (2021-2023), Dave & Buster's, a publicly held dining and entertainment company (2019-2021), and Hibbett Sports, a publicly held athletic specialty retailer (2012-2019) that was subsequently acquired by JD Sports. For over two decades prior, he held roles of increasing responsibility in the finance and accounting departments at The Home Depot, divisions of Newell Rubbermaid, and The Sherwin-Williams Company. Bowman holds a B.S. in Accounting and Finance from Miami University (Ohio) and an MBA from Emory Goizueta Business School, and is a CPA.

Ron Stilwell, Senior Vice President Operations and Patient Experience

Ron Stilwell joined The Joint in 2026. He has successfully utilized his expertise in franchise operations, P&L management, and customer satisfaction to help franchisors grow and maximize profitability. Before his tenure at The Joint, Stilwell served as President and Chief Development Officer of FullSpeed Automotive, a significant automotive aftermarket conglomerate that operates and franchises quick oil change and service centers, starting in 2021.

Beth Gross, Vice President of Human Resources

Beth Gross joined The Joint in September 2024, bringing over two decades of human resources experience. Most recently, she held the position of Vice President of Human Resources at Spear Education, a private equity-owned dental education organization based in Scottsdale, Arizona. In this role, she managed all aspects of organizational development and talent acquisition strategy, and established the employer branding strategy, under which Spear Education was recognized five times as a "Top Companies to Work For in AZ". Gross earned a BA in corporate communications from Arizona State University.

Craig Sherwood, Chief Development Officer

Craig Sherwood joined The Joint in 2025. He has more than 25 years of executive leadership experience in global franchise development within both the fitness and Quick Service Restaurant (QSR) industries. Before joining The Joint, he was the Chief Development Officer for Lumin Fitness, an AI-powered fitness company, where he was responsible for all aspects of Lumin's global franchise development, real estate, design, and construction, and he initiated the strategic direction for the brand.

AI Analysis | Feedback

The Joint Corp. (JYNT) faces several key risks, primarily stemming from its business model transformation and external economic and regulatory pressures.

1. Reliance on the Franchise Model and Franchisee Performance

The Joint Corp. is undergoing a strategic transition to become a "pure-play franchisor," divesting its company-owned clinics. This shift makes the company's financial performance and brand reputation highly dependent on the success and operational consistency of its franchisees. Risks associated with this model include the potential for franchisees to underperform, which directly impacts royalty revenue and could lead to inconsistencies in service quality across locations due to the franchisor's limited control over independent operators. The company's historical disclosures regarding franchise health and the challenges of expansion into new states have also been noted as potential concerns.

2. Labor Shortages and Inflationary Pressures

The company is vulnerable to nationwide labor shortages, particularly in recruiting qualified chiropractors and other staff, which can lead to increased operating costs and even reduced revenues. Inflation further exacerbates this risk by driving up labor expenses and interest rates. Additionally, inflationary pressures could lead to reduced discretionary spending by consumers on services such as chiropractic care, negatively impacting patient volumes and revenue.

3. Regulatory and Legal Risks

The Joint Corp. operates within a highly regulated healthcare industry, with chiropractic practice subject to varying state-level laws, particularly concerning the "corporate practice of chiropractic". Challenges to the company's management agreements with chiropractic professional corporations could significantly disrupt its business model in certain regions. The company has previously faced regulatory inquiries in multiple states, indicating an ongoing threat from evolving state and federal regulations.

AI Analysis | Feedback

The clear emerging threat to The Joint Corp. is the rapid growth and adoption of Digital Therapeutics (DTx) and virtual physical therapy platforms specifically targeting musculoskeletal (MSK) pain management. Companies in this space offer remotely delivered, personalized exercise programs, coaching, and education for conditions like back and neck pain, often covered by employers and health plans. These platforms provide an accessible, non-invasive, and often more cost-effective alternative to in-person chiropractic care, directly competing for a significant portion of The Joint's target market seeking relief and management for MSK issues.

AI Analysis | Feedback

The addressable market for The Joint Corp.'s main product or service, chiropractic care, is the United States.

The U.S. chiropractic market size was approximately USD 13.13 billion in 2022. It reached an estimated USD 21.4 billion in 2024 and is projected to be USD 21.9 billion in 2025. The market is predicted to grow to around USD 18.40 billion by 2030.

AI Analysis | Feedback

The Joint Corp. (JYNT) is anticipated to drive future revenue growth over the next 2-3 years through several strategic initiatives:

  1. Expansion of the Franchise Network and New Clinic Openings: The company is transitioning to a pure-play franchisor model, actively refranchising corporate clinics and focusing on opening new franchised units. This shift is expected to increase franchise royalties and fees. The Joint Corp. aims to complete this transition by 2026, with plans for 30-35 new franchised clinic openings in 2026.

  2. Strategic Pricing Adjustments: The Joint Corp. has implemented a new pricing strategy, incorporating smaller, more frequent price increases and introducing a "Kickstart plan" for supplemental adjustments. These initiatives are designed to enhance revenue per patient visit.

  3. Enhanced Patient Acquisition and Retention through Marketing: The company is intensifying its marketing efforts to attract new patients and improve the retention of existing members. This includes refining brand positioning, media strategies, and digital visibility (SEO), with a focus on chiropractic care for pain relief, attracting lapsed patients, and extending existing memberships.

  4. Broader Market Expansion and Service Offerings: Plans include expanding operations into new markets within the U.S., with potential international expansion beginning in 2027. Additionally, the company is exploring broadening its service offerings, such as through B2B channels and integrated treatments.

AI Analysis | Feedback

Capital Allocation Decisions (Last 3-5 Years)

Share Repurchases

  • The Joint Corp. authorized a $5 million stock repurchase program in June 2025, which was expected to commence in August 2025 and conclude by June 3, 2027.
  • Following the completion of the initial $5 million buyback, the board authorized an additional $12 million for the stock repurchase program in November 2025.
  • For the full year 2025, the company repurchased 1.3 million shares totaling $11.3 million. As of December 31, 2025, $5.7 million remained authorized under the $12 million program.

Capital Expenditures

  • In the first half of 2023, The Joint Corp. invested $4.7 million in the development of greenfield clinics, improvements to existing clinics, the acquisition of a previously owned franchise, and the reacquisition of regional developer territories.
  • The company is undergoing a strategic transformation to become a "pure-play franchisor," which involves refranchising corporate-owned clinics. This strategy aims to shift towards a more capital-light operating model.
  • For a pure-play franchisor model, capital expenditures are projected to be approximately 3% of revenues at an expected mid-2026 run rate.

Better Bets vs. Joint (JYNT)

Peer Outperformance in Health Care Facilities

JYNT has trailed 96% of its 23 Health Care Facilities peers over 5Y. Health Care Facilities ranks 4th of 10 industries in Health Care by median 5Y return.
Share of Health Care Facilities constituents that JYNT has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
23%
of 30 industry peers · -15.3% return
3Y
36%
of 25 industry peers · -11.7% return
5Y
4%
of 23 industry peers · -91.6% return
No Health Care Facilities peer with a comparable growth profile has beaten JYNT by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Facilities is JYNT's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 6 16.2%43.2%90.1% CAH 392% · MCK 346% · COR 168%
Managed Health Care 8 40.4%-5.3%2.3% OSCR 84% · HQY 56% · ELV 17%
Health Care Services 20 21.1%37.6%-0.3% HIMS 239% · RDNT 173% · DGX 76%
Health Care Facilities ← 24 6.0%6.5%-4.5% NHC 271% · THC 261% · ENSG 129%
Health Care Equipment 50 -2.7%-0.2%-21.1% POCI 11050% · UFPT 341% · GKOS 222%
Pharmaceuticals 62 -10.5%14.8%-38.6% LQDA 2472% · INDV 1099% · ETON 1051%
Health Care Supplies 12 14.1%-8.9%-39.7% LNTH 287% · HAE 54% · MMSI 20%
Life Sciences Tools & Services 109 4.3%-11.3%-68.4% SNWV 1757% · MEDP 231% · NTRA 199%
Health Care Technology 21 -25.8%-52.6%-79.2% SPOK 68% · HSTM 3% · VEEV -13%
Biotechnology 364 0.6%-21.7%-79.4% CELZ 1280% · DNTH 1221% · ELVN 1069%
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

JYNTUSPHPLNTLTHXWELMedian
NameJoint US Physi.Planet F.Life TimeXWELL  
Mkt Price8.4482.4749.4940.750.9040.75
Mkt Cap0.11.23.89.10.01.2
Rev LTM598121,4093,18228812
Op Inc LTM279436550-1179
FCF LTM464262-151-134
FCF 3Y Avg564217-67-145
CFO LTM583434899-1183
CFO 3Y Avg677376700-1277

Growth & Margins

JYNTUSPHPLNTLTHXWELMedian
NameJoint US Physi.Planet F.Life TimeXWELL  
Rev Chg LTM9.0%11.3%12.7%12.7%-7.6%11.3%
Rev Chg 3Y Avg67.0%11.9%10.9%16.0%-5.5%11.9%
Rev Chg Q14.4%8.5%7.1%13.7%-7.1%8.5%
QoQ Delta Rev Chg LTM3.4%2.1%1.8%3.4%-1.9%2.1%
Op Inc Chg LTM215.0%11.6%23.5%38.5%24.8%24.8%
Op Inc Chg 3Y Avg6.6%5.1%19.5%35.7%19.0%19.0%
Op Mgn LTM2.8%9.7%30.9%17.3%-38.1%9.7%
Op Mgn 3Y Avg-2.5%10.0%28.6%14.3%-40.4%10.0%
QoQ Delta Op Mgn LTM1.6%-0.4%1.0%0.8%2.1%1.0%
CFO/Rev LTM9.2%10.2%30.8%28.3%-39.8%10.2%
CFO/Rev 3Y Avg27.2%10.8%29.9%24.6%-39.7%24.6%
FCF/Rev LTM7.2%7.9%18.6%-4.7%-47.6%7.2%
FCF/Rev 3Y Avg18.8%9.0%17.2%-2.5%-46.3%9.0%

Valuation

JYNTUSPHPLNTLTHXWELMedian
NameJoint US Physi.Planet F.Life TimeXWELL  
Mkt Cap0.11.23.89.10.01.2
P/S2.11.52.72.90.32.1
P/Op Inc73.215.88.816.5-0.715.8
P/EBIT73.215.98.416.5-0.315.9
P/E31.7-154.316.021.9-0.316.0
P/CFO22.315.08.810.1-0.710.1
Total Yield3.2%0.5%6.2%4.6%-306.9%3.2%
Dividend Yield0.0%1.1%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg2.7%5.4%3.9%-1.4%-214.1%2.7%
D/E0.00.30.80.51.00.5
Net D/E-0.20.30.70.4-0.60.3

Returns

JYNTUSPHPLNTLTHXWELMedian
NameJoint US Physi.Planet F.Life TimeXWELL  
1M Rtn0.0%5.4%-8.7%-9.7%-13.5%-8.7%
3M Rtn-9.6%31.0%-6.6%10.4%-24.4%-6.6%
6M Rtn2.8%13.1%-33.4%57.6%-26.8%2.8%
12M Rtn-15.3%7.8%-51.0%46.4%-19.6%-15.3%
3Y Rtn-11.7%-7.0%8.0%169.2%-73.4%-7.0%
1M Excs Rtn3.3%5.5%-7.5%-8.0%-4.5%-4.5%
3M Excs Rtn-11.6%29.0%-8.6%8.4%-26.4%-8.6%
6M Excs Rtn-12.5%-3.4%-50.7%41.5%-42.0%-12.5%
12M Excs Rtn-31.7%-8.6%-65.7%30.6%-30.2%-30.2%
3Y Excs Rtn-81.0%-77.6%-87.2%83.8%-146.4%-81.0%

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Franchise operations5552474236
Corporate clinics   5944
Total55524710180


Operating Income by Segment
$ Mil20232022202120202019
Franchise operations2017151311
Corporate clinics-30753
Unallocated corporate-20-17-16-12-11
Total-21653


Net Income by Segment
$ Mil202520242023
Franchise operations3-6-10
Total3-6-10


Assets by Segment
$ Mil20232022202120202019
Corporate clinics5256402525
Unallocated cash and cash equivalents and restricted cash191120219
Franchise operations111213107
Unallocated property and equipment31111
Other unallocated assets2141491
Total8793876644


Price Behavior

Price Behavior
Market Price$8.44 
Market Cap ($ Bil)0.1 
First Trading Date11/11/2014 
Distance from 52W High-19.8% 
   50 Days200 Days
DMA Price$8.47$8.83
DMA Trendindeterminatedown
Distance from DMA-0.3%-4.4%
 3M1YR
Volatility35.1%36.5%
Downside Capture29.8792.94
Upside Capture-26.9557.46
Correlation (SPY)10.7%26.6%
JYNT Betas & Captures as of 8/31/2026

 1M2M3M6M1Y3Y
Beta-0.350.410.590.600.810.95
Up Beta-0.030.190.580.810.840.75
Down Beta0.751.610.790.630.771.24
Up Capture-39%-7%34%34%46%57%
Bmk +ve Days10213268138427
Stock +ve Days13213268122346
Down Capture-122%54%68%67%105%102%
Bmk -ve Days11213259113324
Stock -ve Days7203158124385

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with JYNT
JYNT-15.8%36.7%-0.40-
Sector ETF (XLV)24.4%16.1%1.1613.5%
Equity (SPY)16.9%12.9%0.9426.9%
Gold (GLD)19.1%29.3%0.60-2.9%
Commodities (DBC)46.3%20.6%1.73-14.7%
Real Estate (VNQ)4.9%13.6%0.1016.5%
Bitcoin (BTCUSD)-30.6%44.3%-0.7013.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with JYNT
JYNT-39.7%56.9%-0.66-
Sector ETF (XLV)6.4%15.2%0.2425.3%
Equity (SPY)12.9%17.2%0.5738.5%
Gold (GLD)19.1%18.8%0.832.4%
Commodities (DBC)11.2%19.5%0.451.8%
Real Estate (VNQ)1.1%18.8%-0.0533.7%
Bitcoin (BTCUSD)12.5%52.5%0.4224.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with JYNT
JYNT11.2%55.6%0.42-
Sector ETF (XLV)10.6%16.7%0.5125.6%
Equity (SPY)15.1%18.0%0.7236.0%
Gold (GLD)12.1%16.4%0.611.1%
Commodities (DBC)8.3%18.1%0.378.4%
Real Estate (VNQ)4.4%20.7%0.1833.2%
Bitcoin (BTCUSD)62.6%66.2%1.0214.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date8312026
Short Interest: Shares Quantity0.4 Mil
Short Interest: % Change Since 8152026-5.1%
Average Daily Volume0.1 Mil
Days-to-Cover Short Interest6.9 days
Basic Shares Quantity14.2 Mil
Short % of Basic Shares2.8%

Earnings Returns History

Updated 9/9/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/6/20261.3%2.4%1.2%
5/7/20260.2%-5.3%-5.4%
3/12/20262.3%-0.5%8.0%
11/6/2025-3.9%3.5%9.3%
8/7/20250.4%0.7%-0.6%
5/8/2025-5.1%-4.0%13.2%
3/13/20254.6%21.1%-1.3%
1/16/20251.7%2.6%4.8%
...
SUMMARY STATS   
# Positive181413
# Negative71112
Median Positive3.0%7.2%13.2%
Median Negative-5.1%-4.0%-10.3%
Max Positive30.0%29.1%46.1%
Max Negative-37.9%-40.0%-41.8%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/6/20261.3%2.4%1.2%
5/7/20260.2%-5.3%-5.4%
3/12/20262.3%-0.5%8.0%
11/6/2025-3.9%3.5%9.3%
8/7/20250.4%0.7%-0.6%
5/8/2025-5.1%-4.0%13.2%
3/13/20254.6%21.1%-1.3%
1/16/20251.7%2.6%4.8%
11/7/2024-2.3%-5.6%-2.9%
8/8/2024-8.4%-5.7%-10.2%
5/2/202425.3%28.1%15.2%
3/7/202430.0%29.1%41.2%
11/9/202312.9%12.8%29.9%
9/13/20233.6%1.6%-12.6%
5/4/20231.1%-2.6%-10.4%
3/9/20231.5%-1.0%-1.0%
11/3/20222.4%15.4%8.1%
8/4/20226.7%8.4%-16.3%
5/5/2022-37.9%-40.0%-41.8%
2/24/2022-18.8%-30.6%-32.2%
11/4/20210.5%-1.0%-25.9%
8/5/202115.2%6.0%18.2%
5/6/20216.1%-3.8%46.1%
3/4/2021-1.0%1.8%4.4%
11/5/20203.7%25.2%32.8%
SUMMARY STATS   
# Positive181413
# Negative71112
Median Positive3.0%7.2%13.2%
Median Negative-5.1%-4.0%-10.3%
Max Positive30.0%29.1%46.1%
Max Negative-37.9%-40.0%-41.8%

SEC Filings

Expand for More
Report DateFiling DateFiling
06/30/202608/07/202610-Q
03/31/202605/08/202610-Q
12/31/202503/13/202610-K
09/30/202511/07/202510-Q
06/30/202508/12/202510-Q
03/31/202505/09/202510-Q
12/31/202403/14/202510-K
09/30/202411/08/202410-Q
06/30/202408/09/202410-Q
03/31/202405/03/202410-Q
12/31/202303/08/202410-K
09/30/202311/13/202310-Q
06/30/202309/26/202310-Q
03/31/202305/05/202310-Q
12/31/202203/10/202310-K
09/30/202211/04/202210-Q
Collapse to Preview
Report DateFiling DateFiling
06/30/202608/07/202610-Q
03/31/202605/08/202610-Q
12/31/202503/13/202610-K
09/30/202511/07/202510-Q
06/30/202508/12/202510-Q
03/31/202505/09/202510-Q
12/31/202403/14/202510-K
09/30/202411/08/202410-Q
06/30/202408/09/202410-Q
03/31/202405/03/202410-Q
12/31/202303/08/202410-K
09/30/202311/13/202310-Q
06/30/202309/26/202310-Q
03/31/202305/05/202310-Q
12/31/202203/10/202310-K
09/30/202211/04/202210-Q
06/30/202208/05/202210-Q
03/31/202205/06/202210-Q
12/31/202103/14/202210-K
09/30/202111/05/202110-Q
06/30/202108/06/202110-Q
03/31/202105/07/202110-Q
12/31/202003/05/202110-K
09/30/202011/06/202010-Q
06/30/202008/07/202010-Q
03/31/202005/08/202010-Q
12/31/201903/06/202010-K
09/30/201911/08/201910-Q

Recent Forward Guidance

Updated 8/7/2026

Latest: Q2 2026 Earnings Reported 8/6/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 New franchised clinic openingsReported222426-26.2% LoweredGuidance: 32.5 for 2026
2026 System-wide salesReported519.00 Mil535.50 Mil552.00 Mil0 AffirmedGuidance: 535.50 Mil for 2026
2026 System-wide comp salesReported-0.0300.03 0AffirmedGuidance: 0 for 2026
2026 Consolidated Adjusted EBITDAReported12.50 Mil13.00 Mil13.50 Mil0 AffirmedGuidance: 13.00 Mil for 2026


Prior: Q1 2026 Earnings Reported 5/7/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 New franchised clinic openingsReported3032.5350 AffirmedGuidance: 32.5 for 2026
2026 System-wide salesReported519.00 Mil535.50 Mil552.00 Mil0 AffirmedGuidance: 535.50 Mil for 2026
2026 System-wide comp salesReported-0.0300.03 0AffirmedGuidance: 0 for 2026
2026 Consolidated Adjusted EBITDAReported12.50 Mil13.00 Mil13.50 Mil0 AffirmedGuidance: 13.00 Mil for 2026

Q4 2025 Earnings Reported 3/12/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 New franchised clinic openingsReported3032.5350.0% Same NewGuidance: 32.5 for 2025
2026 System-wide salesReported519.00 Mil535.50 Mil552.00 Mil0.7% Higher NewGuidance: 532.00 Mil for 2025
2026 System-wide comp salesReported-0.0300.03 0.5%Higher NewGuidance: -0.01 for 2025
2026 Consolidated Adjusted EBITDAReported12.50 Mil13.00 Mil13.50 Mil15.0% Higher NewGuidance: 11.30 Mil for 2025

Q3 2025 Earnings Reported 11/6/2025

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2025 New clinic openingsReported3032.5350 AffirmedGuidance: 32.5 for 2025
2025 System-wide salesReported530.00 Mil532.00 Mil534.00 Mil-1.5% LoweredGuidance: 540.00 Mil for 2025
2025 Comp salesReported-0.01-0.010   
2025 Consolidated Adjusted EBITDAReported10.80 Mil11.30 Mil11.80 Mil0 AffirmedGuidance: 11.30 Mil for 2025

Insider Activity

Updated 6/12/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Jobson, Charles EDirectBuy51420268.5720,375174,61415,373,329Form
2Jobson, Charles EDirectBuy51420268.57127,6761,094,18315,198,715Form
3Jobson, Charles EDirectBuy42320268.585094,36714,120,990Form
4Jobson, Charles EDirectBuy21720268.5015,397130,87413,984,999Form
5Jobson, Charles EDirectBuy21320268.704483,89814,264,494Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Jobson, Charles EDirectBuy51420268.5720,375174,61415,373,329Form
2Jobson, Charles EDirectBuy51420268.57127,6761,094,18315,198,715Form
3Jobson, Charles EDirectBuy42320268.585094,36714,120,990Form
4Jobson, Charles EDirectBuy21720268.5015,397130,87413,984,999Form
5Jobson, Charles EDirectBuy21320268.704483,89814,264,494Form
6Jobson, Charles EDirectBuy127202610.007257,25016,391,490Form
7Jobson, Charles EDirectBuy127202610.0016,753167,53016,384,240Form
8Jobson, Charles EDirectBuy120920258.4110,00084,10013,582,377Form
9Jobson, Charles EDirectBuy120320258.4113,000109,33013,498,277Form
10Jobson, Charles EDirectBuy112520258.432,08117,54313,420,788Form
11Jobson, Charles EDirectBuy112520258.364,68039,12513,291,949Form
12Jobson, Charles EDirectBuy112520258.5010,00085,00013,599,541Form
13Grandpre, Christopher M DirectBuy822202510.4110,000104,082409,906Form
14Grandpre, Christopher M DirectBuy819202510.7010,000106,978314,333Form
15Grandpre, Christopher M DirectBuy819202510.8814,388156,531210,873Form
Core Cache Last Updated: 9/20/2026